Dr. Hemanth Rao is a longtime neurologist who serves The Neurological Institute in Charlotte, NC, as CEO. Prior to moving to Charlotte, NC, Dr. Hemanth Rao completed his residency at the Long Island Jewish Medical Center, which is an academic and clinical hub of Northwell Health.As part of its educational offerings, Northwell Health operates a residency training program focused on the specialty of neurology. The three-year program provides participants with the skills required to independently practice neurology and meets the training requirements of both the American Board of Psychiatry and Neurology and the Accreditation Council for Graduate Medical Education. Residents in the program work alongside clinicians at several teaching sites, with each receiving extensive personal attention and gaining exposure both to the general neurology field and a range of sub-specializations, including movement disorders, epilepsy, strokes, and neuro-oncology, among others.Beyond this, the residents participate in various rounds and conferences and engage in the program’s outpatient clinics, which simulate the private-practice setting and thus place the standards of care provided to patients as a priority.
Dr. Hemanth Rao, the president and CEO of the Neurological Institute of Charlotte, NC, also takes an active role in clinical research into treatments for brain and nerve disorders. Dr. Hemanth Rao of Charlotte, NC, has contributed to several new approaches targeting Alzheimer's disease.In developing treatments for Alzheimer's disease, one of the most significant challenges is the blood-brain barrier. This thin membrane, designed to protect the brain from infectious agents, causes a problem for researchers in that it also prevents crucial therapeutic agents from entering the brain.Now, however, a team of scientists from the Queensland Brain Institute has found that ultrasound waves may be effective in helping drugs to cross that barrier. The researchers were able to use scanning ultrasonography to deliver antibodies to the brains of mice exhibiting symptoms of Alzheimer's. This treatment proved effective in reducing the number of the tau proteins that contribute to disease progression, thus mitigating symptoms.The team believes that this treatment may be similarly effective in reducing tau concentrations in human patients. If so, the technique could also prove promising in treating other neurological conditions, such as multiple sclerosis and Parkinson's disease.
